Cardinal Health is getting pummeled on mixed results — here's our plan for stock

May 1, 2026 - 04:35

Shares of Cardinal Health tumbled on Wednesday after the company reported a mixed bag of financial results for its latest quarter. The healthcare services giant posted earnings that fell short of analyst expectations in some key segments, while revenue figures came in slightly above forecasts. Investors reacted swiftly, sending the stock down by more than 5% in morning trading.

The company's pharmaceutical distribution business, which accounts for the bulk of its revenue, showed steady growth. However, margins in that division were thinner than anticipated, raising concerns about pricing pressure and operational costs. Meanwhile, Cardinal Health's medical segment, which supplies hospitals and clinics with surgical gloves, masks, and other equipment, saw a noticeable slowdown in demand compared to the previous year.

For those who bought the stock just before the earnings release, the timing has been painful. We initiated a position in early March, hoping the company would benefit from steady prescription drug volumes and a rebound in elective medical procedures. That bet did not pay off this quarter. Hindsight is always clear, and in this case, the warning signs were there: rising competition in drug distribution and lingering supply chain inefficiencies in the medical supply chain.

Looking ahead, the company reaffirmed its full-year profit guidance, which suggests management believes the current headwinds are temporary. But the market is skeptical. With the stock now trading near its 52-week low, the key question is whether this is a buying opportunity or a value trap. The next few quarters will be critical in determining if Cardinal Health can stabilize its margins and regain investor confidence.